A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

Aurora Kinase A Inhibition Leads to p73-Dependent Apoptosis in p53-Deficient Cancer Cells

(2008) Altaf A. Dar et al.   CANCER RESEARCH

DNA Damage Detection and Repair Pathways--Recent Advances with Inhibitors of Checkpoint Kinases in Cancer Therapy

(2008) S. Ashwell et al.   CLINICAL CANCER RESEARCH

Polo and Aurora kinases—lessons derived from chemical biology

(2008) Stephen Taylor et al.   CURRENT OPINION IN CELL BIOLOGY

The MDM2 Inhibitor Nutlins as an Innovative Therapeutic Tool for the Treatment of Haematological Malignancies

(2008) Paola Secchiero et al.   CURRENT PHARMACEUTICAL DESIGN

Phase I Dose Escalation and Pharmacokinetic Study of BI 2536, a Novel Polo-Like Kinase 1 Inhibitor, in Patients With Advanced Solid Tumors

(2008) Klaus Mross et al.   JOURNAL OF CLINICAL ONCOLOGY

Kinase requirements in human cells: I. Comparing kinase requirements across various cell types

(2008) D. A. Grueneberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

(2008) S. Jones et al.   SCIENCE

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE